<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04483245</url>
  </required_header>
  <id_info>
    <org_study_id>DE MAISTRE 2019</org_study_id>
    <nct_id>NCT04483245</nct_id>
  </id_info>
  <brief_title>Platelet Activation by a Collagen Analogue in Hemorrhagic Situations</brief_title>
  <acronym>CAPTURE</acronym>
  <official_title>Platelet Activation by a Collagen Analogue in Hemorrhagic Situations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dijon University Hospital and the Dijon-based NVH Medicinal Company have developed a
      recombinant mini-collagen NVH020B with platelet and Willebrand factor binding activity. Its
      small size and granular, non-fibrillar presentation make it suitable for use as an injectable
      hemostat in patients with a hemorrhage or other emergency under antiplatelet therapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The expression of P-selectin and activated GPIIb/IIIa (PAC1) at the surface of platelets in flow cytometry in response to NVH020B.</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>These 2 markers are absent on the surface of resting platelets. The expression of these 2 markers will make it possible to evaluate the role of the mini-collagen as an activator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet aggregation rate in response to NVH020B</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Collagen Analog</condition>
  <condition>Platelet Activation</condition>
  <condition>Hemorrhage</condition>
  <arm_group>
    <arm_group_label>controls</arm_group_label>
    <description>persons free of hemorrhage or haemostasis disorder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Haemorrhagic</arm_group_label>
    <description>Acute hemorrhagic patient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ECMO</arm_group_label>
    <description>ECMO surgery patient with hemorrhagic complication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>polytrauma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Platelet disorder</arm_group_label>
    <description>Patient with an identified platelet disorder or treated with antiplatelet agents</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood sampling</description>
    <arm_group_label>ECMO</arm_group_label>
    <arm_group_label>Haemorrhagic</arm_group_label>
    <arm_group_label>Platelet disorder</arm_group_label>
    <arm_group_label>controls</arm_group_label>
    <arm_group_label>polytrauma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients coming for a consultation at the Resouce Centre for Haemorrhagic Diseases and
        Coagulopathies in the Internal Medicine and Haematology Department. Patients admitted to
        the Emergency Department, and patients admitted to the operating theatre by the Surgical
        Intensive Care Unit, the Neurovascular Emergency Department, or the Neurosurgery
        Department.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - person who has given their non-opposition to inclusion

          -  adult

          -  Healthy volunteers or controls (patients seen in consultation, without history of
             hemmorhage, etc.).

        or

          -  patients with acute bleeding: polytraumatized, or hemorrhage or intracerebral
             haemorrhage, or bleeding complications at the end surgery (in particular cardiac
             surgery with ECMO) or

          -  patients with antiplatelet therapy or

          -  patients with thrombocytopenia/thrombopathy

        Exclusion Criteria:

          -  protected adults (curatorship, guardianship)

          -  person deprived of their liberty by judicial or administrative decision

          -  pregnant, parturient or breastfeeding woman

          -  person unable to express their non-opposition

          -  platelet transfusion on initial management
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emmanuel DE MAISTRE</last_name>
    <phone>03.80.29.32.57</phone>
    <phone_ext>+33</phone_ext>
    <email>Emmanuel.demaistre@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Emmanuel DE MAISTRE</last_name>
      <phone>03.80.29.32.57</phone>
      <phone_ext>+33</phone_ext>
      <email>Emmanuel.demaistre@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 17, 2020</study_first_submitted>
  <study_first_submitted_qc>July 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

